Current and emerging antiviral treatments for hepatitis C infection

British Journal of Clinical Pharmacology

Volumn 75, Issue 4, 2013, Pages 931-943

  Doyle, Joseph S ^a,b,c   Aspinall, Esther ^g   Liew, Danny ^d   Thompson, Alexander J ^e,f,h   Hellard, Margaret E ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Direct acting antiviral; Hepatitis C virus; Polymerase inhibitors; Protease inhibitors

Indexed keywords

ALISPORIVIR; ANA 733; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; DANOPREVIR; ERYTHROPOIETIN; GI 5005; IMMUNOMODULATING AGENT; IMO 2125; INTERLEUKIN 28B; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MERICITABINE; MICRORNA 122; MIRAVIRSEN; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; TARIBAVIRIN; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; MIXED INFECTION; PRIORITY JOURNAL; RNA GENE; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DRUGS, INVESTIGATIONAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MODELS, BIOLOGICAL; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84875077230     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04419.x     Document Type: Article

References (90)

1. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
3. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.
4. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-244.
6. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212-223.
7. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am 2010; 39: 649-658.
8. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009; 50: 402-411.
9. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.
10. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 265-274.
11. Doyle JS, Sacks-Davis R, Hellard ME. Acute hepatitis C infection: new approaches to surveillance, treatment and prevention. Curr Hepatitis Rep 2012; doi: 10.1007/s11901-012-0143-5. in press.
12. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
13. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
14. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-1009.
15. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
16. Holmes JA, Sievert W, Thompson AJ. IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection. Biomark Med 2011; 5: 461-478.
17. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
18. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, Herrmann E, Lotsch J, Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
19. Vezali E, Aghemo A, Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-2138.
20. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651.
21. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
22. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609.
23. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.
24. Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, Andriulli A, Craxi A. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol 2009; 51: 675-681.
25. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540.
26. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Goncales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-1628.
27. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
28. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
29. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, Van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM. Effective treatment of injecting drug users with recently acquired hepatitis C virus Infection. Gastroenterology 2010; 138: 123-135.
30. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-1998.
31. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nature reviews. Microbiology 2007; 5: 453-463.
32. Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011; 40: 481-494.
33. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3: 191-202.
34. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342-355.
35. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
36. Foote BS, Spooner LM, Belliveau PP. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011; 45: 1085-1093.
37. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718.
38. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
39. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
40. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
41. Vierling JM. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE Study. Hepatology 2011; 54 (Suppl. 1): A931.
42. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
43. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
44. Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, Larrey D, Cacoub P, Ledinghen VD, Bourlière M, Bernard PH, Riachi G, Alric L, Samuel D, Barthe Y, Fontaine H, Carrat F, Bronowicki J-P, ANRS C020 CUPIC Study Group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). J Hepatol 2012; 56 (Suppl. 2): S4.
45. Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P. Future treatment of patients with HCV cirrhosis. Liver Int 2012; 32: 113-119.
46. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mar E. Clinical pharmacology of boceprevir: metabolism, excretion and drug-drug interactions. Conference on Retroviruses and Opporunistic Infections, Boston. 2011.
47. Van Heeswijk R, Vandevoorde A, Boogaerts G, Vangeneugden T, de Paepe E, Polo R, Van Solingen-Ristea R, de Backer K, Garg V, Beumon M. Interactions with telaprevir. Conference on Retroviruses and Opporunistic Infections, Boston. 2011.
48. Fried MW. TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. Hepatology 2011; 54 (Suppl. 1): LB5.
49. Petry AS, Fraser IP, Van Dyck K, Nachbar RB, De Lepeleire I, Robberechts M, Han L, Palcza J, Moiseez V, Kobalava ZD, Uhle M, Wagner F, O'Mara E, Wagner JA. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype-1 and -3 HCV-infected patients. Hepatology 2011; 54 (Suppl. 1): 1364A.
50. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
51. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey M. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 2011; 54 (Suppl. 1): 377A.
52. Gane E, Stedman C, Anderson J, Hyland R, Hindes R, Symonds W, Berrey M. 100% Rapid Virologic Response for PSI-7977 + Ribavirin in Genotype 1 Null Responders (ELECTRON): early Viral Decline Similar to that Observed in Genotype 1 and Genotype 2/3 Treatment-naïve Patients Conference on Retroviruses and Opporunistic Infections, Seattle. 2012:54LB.
53. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, DeJesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen DM, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, DeMicco MP, Strohecker JS, Hyland RH, Mader M, Albanis E, Symonds WT, Berrey MM. Once-daily PSI-7977 plus PEG/RBV in treatment-naïve patients with HCV Gt1: robust end of treatment response rates are sustained post-treatment. Hepatology 2011; 54 (Suppl. 1): 472A.
54. Pockros P, Jensen D, Tsai N. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment naïve HCV G 1 and 4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011; 54 (Suppl. 1): S538.
55. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
56. Larrey D, Benhamou Y, Lohse AW, Trepo C, Moelleken C, Bronowicki J-P. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 2009; 50: S383.
57. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, Holzmann H, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567.
58. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
59. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki J, Abrams GA, Brau N, Morris DW, Thuluvath P, Reindollar R, Yin PD, Diva U, Hindes R, McPhee F, Gao M, Thiry A, Schnittman S, Hughes EA. First report of SVR12 for a NS5a replication complex inhibitor BMS-790052 in combination with PEG-IFNa-2a and RBV: phase 2a trial in treatment-naive HCV-genotype-1 subjects. J Hepatol 2011; 54 (Suppl. 1): S544-545.
60. Plaza Z, Soriano V, Vispo E, Del Mar Gonzalez M, Barreiro P, Seclen E, Poveda E. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 2012; 17: 921-926.
61. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhalm NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
62. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198: 800-807.
63. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639.
64. Crabbe R, Vuagniaux G, Dumont JM, Nicolas-Metral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs 2009; 18: 211-220.
65. Flisiak R, Pawlotsky J, Crabbé R, Calistru PI, Kryczka W, Haussinger D, Mazella G, Romero M, Purcea D, Vuagniaux G, Bao W, Avila C, Zeuzem S. Once daily alisporivir (Deb025) plus PEGIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients. J Hepatol 2011; 54 (Suppl. 1): S2.
66. Puyang X, Poulin DL, Mathy JE, Anderson LJ, Ma S, Fang Z, Zhu S, Lin K, Fujimoto R, Compton T, Wiedmann B. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrobial Agents Chemother (Bethesda) 2010; 54: 1981-1987.
67. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
68. Janssen HLA. A randomized, double-blind, placebo (PLB) controlled safety and antiviral proof of concept study of miravirsen (MIR), an oligonucleotide targeting MIR-122, in treatment naïve patients with genotype 1 (GT1) chronic HCV infection. 62th American Association for the Study of Liver Diseases, San Francisco. 2011.
69. Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol 2010; 44: 504-509.
70. Lee J, Wu CCN, Lee KJ, Chuang T-H, Katakura K, Liu Y-T, Chan M, Tawatao R, Chung M, Shen C, Cottam HB, Lai MMC, Raz E, Carson DA. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 2006; 103: 1828-1833.
71. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW. Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther 2011; 34: 443-453.
72. Rodriguez-Torres M, Ghalib RH, Gordon SC, Lawitz E, Patel K, Pruitt R. IMO-2125, a TLR9 agonist, induces immune responses which correlate with reductions in viral load in null responder HCV patients. Hepatology 2010; 52 (4 Suppl.): 336A.
73. McHutchison JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, Di Bisceglie AM, Gordon SC, Lee WM, Guo Z, King TH, Armstrong B, Rodell TC, Apelian D. Pharmacogenomic analysis reveals improved virologic response in all IL-28B genotypes in naive genotype 1 chronic HCV patients treated with GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin. J Hepatol 2010; 52 (Suppl. 1): S457.
74. Jacobson IM, McHutchison JG, Boyer TD, Schiff ER, Everson GT, Pockros PJ, Chasen RM, Vierling JM, Lawitz EJ, Kugelmas M, Tsai NC, Shiffman ML, Buynak RJ, Sheikh AM, Armstrong B, Rodell TC, Apelian D. GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin significantly improves virologic response and ALT normalization at end-of-treatment and improves SVR24 compared to PEG-IFN /ribavirin in genotype-1 chronic HCV patients. J Hepatol 2010; 52 (Suppl. 1): S465-466.
75. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson G, Fallón M, Ferenci P, Flisiak R, George J, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Romas E, Lopez-Talavera JC, Muir A, EMERGE Study Group. Pegylated interferon-lambda (PegIFN-lambda) shows superior viral response with improved safety and tolerability versus PegIFNα-2a In HCV patients (Gl/2/3/4): emerge Phase IIb Through Week 12. J Hepatol 2011; 54 (Suppl. 1): S538-539.
76. Nelson DR, Rustgi V, Balan V, Sulkowski MS, Davis GL, Muir AJ, Lambiase LR, Dickson RC, Weisner RH, Fiscella M, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009; 7: 212-218.
77. Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, Heise J, Chun E, Pockros PJ. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naive patients with chronic hepatitis C: ViSER1 results. Hepatology 2009; 50: 717-726.
78. Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E, Rodriguez-Torres M. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J Hepatol 2010; 52: 32-38.
79. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
80. Robotin MC, Copland J, Tallis G, Coleman D, Giele C, Carter L, Spencer J, Kaldor JM, Dore GJ. Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol 2004; 19: 283-288.
81. Grebely J, deVlaming S, Duncan F, Viljoen M, Conway B. Current approaches to HCV infection in current and former injection drug users. J Addict Dis 2008; 27: 25-35.
82. Hellard M, Jenkinson R, Higgs P, Stoove M, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012; 196: 638-641.
83. Martin NK, Vickerman P, Foster GR, Hutchinson S, Goldberg D, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J Hepatol 2011; 54: 1137-1144.
84. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
85. Lawitz E, Jacobson IM, Godofsky E, Foster GR, Flisiak R, Bennett M, Ryan M, Hinkle J, Simpson J, McHutchison J, Oldach D. A phase 2b trial comparing 24 to 48 weeks treatment with tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection. J Hepatol 2011; 54 (Suppl. 1): S181.
86. Foster GR, Buggisch P, Marcellin P, Zeuzem S, Agarwal K, Manns M, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Shelton M, Arterburn S, Lee W, McHutchison J, Delaney W, Oldach D. Four-week treatment with GS-9256 and tegobuvir (GS-9190), ± RBV ± PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients. J Hepatol 2011; 54 (Suppl. 1): S172.
87. Zeuzem S, Foster GR, Fried MW, Hezode C, Hirschfleld GM, Nikitin I, Poordad F, Lenz O, Peeters M, Sekar V, Smedt GD. 1376 The Aspire Trial: TMC435 in treatment-experienced patients with genotype-1 HCV infection who have failed previous PEGIFN/RBV treatment. J Hepatol 2011; 54 (Suppl. 1): S546.
88. Bronowicki J-P, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourliere M, Hezode C, Massoud O, Abrams GA, Ratziu V, Thiry A, Llamoso C, Hughes EA, Hindes RG. BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C I nfection. J Hepatol 2011; 54 (Suppl. 1): S472.
89. Larrey P, Carenco C, Guyader D, Boyer N, Benhamou Y, Daniélou H, Pageaux G-P, Rouzier R, Marcellin P. High sustained virological response (SVR) rate after danoprevir for only 14 days associated with PEG-interferon alfa-2a and ribavirin in treatment-naive chronic HCV genotype 1 patients. J Hepatol 2011; 54 (Suppl. 1): S481.
90. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-2055.